Bought
~$51K6,400 sh @ $7.91
Traded May 27 · filed 1 day later
A ADMA Biologics director paid $51K out of pocket for ADMA Biologics shares.
Loading…
Traded May 11, 2026 · Filed May 12, 2026
A ADMA Biologics director paid $100K out of pocket for ADMA Biologics shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$100,125
Shares × reported transaction price
$100K–$500K
+2.6%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
5 days after results of May 6, 2026, 86 days before results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.7% | −0.1% | +0.8% |
| 30 days | −3.4% | −0.1% | −3.3% |
| 90 days | +16.5% | +3.8% | +12.7% |
Past results only. Not a forecast.
Traded May 27 · filed 1 day later
A ADMA Biologics director paid $51K out of pocket for ADMA Biologics shares.
Traded May 12 · filed 2 days later
A ADMA Biologics director paid $100K out of pocket for ADMA Biologics shares.
Traded Apr 1 · filed 3 days later
Routine share withholding; mechanical by default.
Jerrold B Grossman, Director's past purchases, 90 days after disclosure: 3 buys, median +12.7% vs S&P 500, beat it 3 of 3 times. Past results, not a forecast.